Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Total Non-Current Liabilities (2021 - 2025)

Korro Bio's Total Non-Current Liabilities history spans 5 years, with the latest figure at $60.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 5.85% year-over-year to $60.6 million, compared with a TTM value of $60.6 million through Dec 2025, down 5.85%, and an annual FY2025 reading of $60.6 million, down 5.85% over the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $60.6 million at Korro Bio, down from $61.0 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $64.4 million in Q4 2024, with the low at $8.9 million in Q4 2022.
  • Average Total Non-Current Liabilities over 5 years is $49.8 million, with a median of $53.8 million recorded in 2021.
  • Year-over-year, Total Non-Current Liabilities plummeted 83.64% in 2022 and then surged 557.45% in 2024.
  • Tracing KRRO's Total Non-Current Liabilities over 5 years: stood at $54.4 million in 2021, then plummeted by 83.64% to $8.9 million in 2022, then surged by 469.01% to $50.7 million in 2023, then increased by 26.93% to $64.4 million in 2024, then decreased by 5.85% to $60.6 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Total Non-Current Liabilities are $60.6 million (Q4 2025), $61.0 million (Q3 2025), and $63.9 million (Q2 2025).